Company
Upjohn
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
13
12 still marketed
Novel approvals
8
Approvals since 2021
0
Originals and new uses
Phase 3 trials
145
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Lyrica new use Priority reviewMay 23, 2019
- Lyrica new use Priority reviewMay 23, 2019
- Celebrex new use Jun 28, 2018
- Lyrica new use Priority reviewMay 3, 2018
- Lyrica new use Priority reviewMay 3, 2018
- Lyrica Cr approved Oct 11, 2017
- Lipitor new use Jun 23, 2017
- Lyrica new use Dec 22, 2016
- Lyrica new use Dec 22, 2016
- Lyrica new use Feb 28, 2013
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (12)
Newest FDA action first.
- Inspra Eplerenone · 2002
- Lyrica Pregabalin · 2004
- Lyrica Pregabalin · 2010
- Lyrica Cr Pregabalin · 2017
- Celebrex Celecoxib · 1998
- Lipitor Atorvastatin Calcium · 1996
- Effexor Xr Venlafaxine Hydrochloride · 1997
- Xanax Xr Alprazolam · 2003
- Xanax Alprazolam · 1981
- Xalatan Latanoprost · 1996
- Relpax Eletriptan Hydrobromide · 2002
- Detrol Tolterodine Tartrate · 1998
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.